SCHEMBL633872

SCHEMBL633872

O=C(Nc1ccc(Cl)cc1)c1sccc1NCc1c[nH]c2ncccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.59
CYP3A4 P08684 2/20 0.51
RAF1 P04049 1/20 0.51
LCK P06239 1/20 0.51
RET P07949 1/20 0.51
KIT P10721 1/20 0.51
MAP3K20 Q9NYL2 1/20 0.51
RIPK3 Q9Y572 1/20 0.51
ADORA2A P29274 1/20 0.48
FLT1 P17948 2/20 0.43
RAB9A P51151 1/20 0.42
DRD4 P21917 5/20 0.40
DRD2 P14416 4/20 0.40
DRD3 P35462 4/20 0.40
TSHR P16473 2/20 0.40
CACNA1F O60840 1/20 0.40
CYP1A2 P05177 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3395765 0.86 KDR (0.71) KDRCYP3A4RAF1LCKRET
SCHEMBL633661 0.85 KDR (0.60) KDRCYP3A4RAF1LCKRET
SCHEMBL633692 0.84 KDR (0.45) KDRCYP3A4RAF1LCKRET
SCHEMBL27615043 0.83 KDR (0.44) KDRCYP3A4RAF1LCKRET
SCHEMBL635166 0.82 KIT (0.55) KDRCYP3A4RAF1LCKRET
SCHEMBL632357 0.81 KDR (0.73) KDRCYP3A4RAF1LCKRET
SCHEMBL857016 0.79 GPR84 (0.59) CYP3A4DRD4DRD2DRD3TSHR
SCHEMBL429443 0.75 KDR (1.00) KDRKITFLT1RAB9ALMNA
SCHEMBL13409674 0.74 KDR (0.55) KDRCYP3A4RAF1LCKRET
SCHEMBL1266995 0.73 MET (0.51) KDRCYP3A4KITADORA2ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP claimed
JP-4685755-B2 2011-05-18 JP claimed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO claimed
CN-100471841-C (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2009-03-25 CN claimed
EP-1590328-A4 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2007-09-19 EP claimed
CN-1723200-A (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2006-01-18 CN claimed
EP-1590328-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2005-11-02 EP claimed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US claimed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US claimed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO claimed
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP disclosed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7524859-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2009-04-28 US disclosed
CN-100471841-C (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2009-03-25 CN disclosed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US disclosed
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds CREW ANDREW P (US) 2005-09-01 US disclosed
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds OSI PHARMACEUTICALS, INC. 2005-07-14 US disclosed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US disclosed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds ABL1, NAT1, KRAS KDR 869/4885CYP3A4 150/4885RAF1 649/4885
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds AADAC, PAM, TPMT KDR 2418/4885CYP3A4 870/4885RAF1 3013/4885
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds PCNA, MKI67, TPMT KDR 1769/4885CYP3A4 3666/4885RAF1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.